Cortronix Biomedical Advancement (PNAM) 10-K 21 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Aug. 31, 2013	Feb. 04, 2014	Feb. 28, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'Cortronix Biomedical Advancement Technologies Inc.	'	'
Entity Central Index Key	'0001380713	'	'
Document Type	'10-K	'	'
Document Period End Date	31-May-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--08-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$25,600,000
Entity Common Stock, Shares Outstanding	'	349,500,000	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Balance_Sheets_Unaudited

Balance Sheets (Unaudited) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Current assets	'	'
Cash	$640	$31,686
Prepaid expenses	60,377	1,813
Total current assets	61,017	33,499
Security deposit	3,390	3,390
Equipment and furniture, net	20,962	6,690
Total Assets	85,369	43,579
Current liabilities	'	'
Accounts payable and accrued liabilities	77,625	1,161
Accounts payable, related parties	28,827	'
Accrued interest	116,473	'
Payroll liabilities	9,943	2,604
Advances from related parties	85,008	50,000
Notes payable	819,374	'
Total Current Liabilities	1,137,250	53,765
STOCKHOLDERS DEFICIENCY	'	'
Common stock: 800,000,000 shares authorized, at $0.001 par value 287,000,000 and 175,000,000 shares issued and outstanding at May 31, 2013 and August 31, 2012, respectively	287,000	175,000
Capital in excess of par value	-888,702	-174,250
Deficit accumulated during the development stage	-450,179	-10,936
Total Stockholders Deficiency	-1,051,881	-10,186
Total Liabilities and Stockholders Deficiency	$85,369	$43,579

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Aug. 31, 2013	Aug. 31, 2012	Oct. 04, 2006
Statement of Financial Position [Abstract]	'	'	'
Common stock, par value	$0.00	$0.00	$0.00
Common stock, shares authorized	800,000,000	800,000,000	100,000,000
Common stock, shares issued	287,000,000	175,000,000	'

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (USD $)	1 Months Ended	12 Months Ended	13 Months Ended
	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2013
Income Statement [Abstract]	'	'	'
REVENUE	'	'	'
EXPENSES	'	'	'
Professional fees	'	43,198	43,198
Patent fees	'	19,792	19,792
Salary and wages	9,615	183,269	192,884
Depreciation	'	1,018	1,018
Other general and administrative expenses	1,321	117,400	118,721
OPERATING LOSS	-10,936	-364,677	-375,613
Other income and expense	'	'	'
Interest expense	'	-74,566	-74,566
NET LOSS	($10,936)	($439,243)	($450,179)
Basic and diluted loss per share	$0	$0	'
Weighted average number of shares outstanding, basic and diluted	175,000,000	283,625,658	'

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	1 Months Ended	12 Months Ended	13 Months Ended
	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($10,936)	($439,243)	($450,179)
Adjustment to reconcile net loss to net cash (used in) operating activities:	'	'	'
Depreciation	'	1,018	1,018
Accrued interest	'	74,566	74,566
Damage deposit	-3,390	'	-3,390
Prepaid expenses	-1,813	-58,564	-60,377
Payroll liabilities	2,604	7,339	9,943
Advances from related parties	'	50,650	50,650
Accounts payable and accrued liabilities	1,161	56,762	57,923
Accounts payable, related parties	'	28,827	28,827
Net cash provided by (used) in operating activities	-12,374	-278,645	-291,019
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Acquisition of equipment and furniture	-6,690	-15,290	-21,980
Cash from acquisition	'	22,889	22,889
Net cash provided by ( used) in investing activities	-6,690	7,599	909
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from notes	50,000	240,000	290,000
Proceeds from issuance of common stock	750	'	750
Net cash provided by financing activities	50,750	240,000	290,750
Increase (decrease) in cash during the period	31,686	-31,046	640
Cash, beginning of period	'	31,686	'
Cash, end of period	31,686	640	640
Supplemental non-cash investing activities:	'	'	'
Accounts payable acquired from reverse acquisition	'	19,702	19,702
Accrued interest acquired from reverse acquisition	'	41,907	41,907
Advances from related parties acquired from reverse acquisition	'	34,358	34,358
Notes payable acquired from reverse acquisition	'	579,373	579,373
Loan receivable	'	-50,000	-50,000
Total	'	$625,340	$625,340

Shareholders_Equity

Shareholders Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit During the Development Stage	Total
Beginning balance, amount at Aug. 02, 2012	$0	$0	$0	$0
Beginning balance, shares at Aug. 02, 2012	0	'	'	'
Issuance of common shares for cash, August 3, 2012, shares	750,000	'	'	'
Issuance of common shares for cash, August 3, 2012, amount	750	'	'	750
Recapitalization effect on issuance of common shares, shares	174,250,000	'	'	'
Recapitalization effect on issuance of common shares, amount	174,250	-174,250	'	0
Net loss for the period	'	'	-10,936	-10,936
Ending balance, amount at Aug. 31, 2012	175,000	-174,250	-10,936	-10,186
Ending balance, shares at Aug. 31, 2012	175,000,000	'	'	'
Recapitalization on September 11, 2012, shares	112,000,000	'	'	'
Recapitalization on September 11, 2012, amount	112,000	-714,452	'	-602,452
Net loss for the period	'	'	-439,243	-439,243
Ending balance, amount at Aug. 31, 2013	$287,000	($888,702)	($450,175)	($1,051,881)
Ending balance, shares at Aug. 31, 2013	287,000,000	'	'	'

Shareholders_Equity_Parentheti

Shareholders Equity (Parenthetical)	Sep. 11, 2012	Aug. 04, 2012
Statement of Stockholders' Equity [Abstract]	'	'
Shares issued	112,000,000	175,000,000

Note_1_Organization_and_Basis_

Note 1 - Organization and Basis of Presentation	12 Months Ended
	Aug. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 1 - Organization and Basis of Presentation	'
	1. ORGANIZATION AND BASIS OF PRESENTATON
	CorTronix Biomedical Advancement Technologies Inc. (formerly Pana-Minerales S.A.) (the “Company”), was incorporated under the laws of the State of Nevada on October 4, 2006 with authorized capital stock of 100,000,000 shares at $0.001 par value.  The Company was originally organized for the purpose of acquiring and developing mineral properties.
	On August 15, 2012, we entered into an acquisition agreement with CorTronix Technologies Inc. (“CorTronix”).  The officer and director of CorTronix, Yoel Palomino is also the officer and director of the Company, and is the developer of the technology held by CorTronix. CorTronix was incorporated solely for the purpose of this acquisition and its only operations were the development of a proprietary technology known as Corlink.  Corlink, is an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. Under the terms of the acquisition agreement CorTronix became a wholly owned subsidiary of the Company and is now the operational company which will continue with the commercialization of the technology it holds. Under the terms of the agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the Company. The Share Exchange Agreement was completed on September 11, 2012.
	The business combination was accounted for as a reverse acquisition and recapitalization using accounting principles applicable to reverse acquisitions whereby the financial statements subsequent to the date of the transaction are presented as a continuation of CorTronix.  Under reverse acquisition accounting CorTronix (subsidiary) is treated as the accounting parent (acquirer) and the Company (parent) is treated as the accounting subsidiary (acquiree). All outstanding shares have been restated to reflect the effect of the business combination.
	Both the Company and its subsidiary CorTronix have a fiscal year end of August 31.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2013
Accounting Policies [Abstract]	'
Note 2 - Summary of Significant Accounting Policies	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	These consolidated financial statements include the accounts of CorTronix Biomedical Advancement Technologies Inc., and its wholly-owned subsidiary, CorTronix Technologies Inc. All intercompany balances and transactions have been eliminated in consolidation.
	Development- Stage
	CorTronix Biomedical Advancement Technologies Inc. is a development-stage company as defined in Accounting Standards Codification (“ASC”) 915 Development-Stage Entities, as it is developing an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. There have been no revenues from planned principal operations or sales from August 3, 2012 (date of inception) through to August 31, 2013. Consequently, cumulative amounts are presented in these consolidated financial statements.
	Cash and Cash Equivalents
	For purposes of the consolidated statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
	Property, Plant and Equipment
	Property, plant and equipment are recorded at cost. Depreciation and amortization of property and equipment are calculated using the straight-line method over the assets’ estimated useful lives as follows: computer hardware and software (three years), leasehold improvements (the shorter of five years or lease life), furniture and fixtures (five years) and equipment (five to ten years).
	Maintenance and repairs are charged to expense as incurred. Significant renewals and betterments are capitalized. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations.
	Research and Development
	Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for project development activities, and that have alternative future uses, both in project development, marketing or sales, will be capitalized classified as property, plant and equipment and depreciated over their estimated useful lives. To date, research costs, including amounts paid for man hours allocated to ongoing technology development, have been expensed when incurred.
	Accounting Methods
	The Company recognizes income and expenses based on the accrual method of accounting.
	Dividend Policy
	The Company has not yet adopted a policy regarding payment of dividends.
	Basic and Diluted Net Income (loss) Per Share
	Basic net income (loss) per share amounts are computed based on the weighted average number of shares actually outstanding. Diluted net income (loss) per share amounts are computed using the weighted average number of common and common equivalent shares outstanding as if shares had been issued on the exercise of any common share rights unless the exercise becomes antidilutive and then the basic and diluted per share amounts are the same.
	Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax bases of the assets and liabilities and are measured using the enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recorded, when it is more likely than not, that such tax benefits will not be realized. As of August 31, 2013, the Company had a deferred tax asset and related valuation allowance of $182,300, which begins to expire in 2032, related to its current operations.
	Section 382 of the Internal Revenue Code imposes limitations on net loss carryforwards when there is a change in control. Due to the change of business and management, the Company has assumed loss carryforwards related to the Company’s prior operations will not be available to offset future taxable income.
	Advertising and Market Development
	The Company expenses advertising and market development costs as incurred.
	Impairment of Long-lived Assets
	The Company reviews and evaluates long-lived assets for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The assets are subject to impairment consideration under ASC 360-10-35-17 if events or circumstances indicate that their carrying amounts might not be recoverable. When the Company determines that an impairment analysis should be done, the analysis will be performed using rules of ASC 930-360-35, Asset Impairment, and 360-10-15-3 through 15-5, Impairment or Disposal of Long-Lived Assets.
	Financial Instruments
	The carrying amounts of financial instruments are considered by management to be their fair value due to their short term maturities.
	Estimates and Assumptions
	Management uses estimates and assumptions in preparing financial statements in accordance with general accepted accounting principles. Those estimates and assumptions affect the reported amounts of the assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were assumed in preparing these financial statements.
	Statement of Cash Flows
	For the purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents.
	Recent Accounting Pronouncements
	There are several new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of May 31, 2013, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company.

Note_3_Going_Concern

Note 3 - Going Concern	12 Months Ended
	Aug. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 3 - Going Concern	'
	3. GOING CONCERN
	The Company will need additional working capital to service its debt, for ongoing operational expenses and to continue with the commercialization of its development stage technology, which raises substantial doubt about its ability to continue as a going concern. While management of the Company has developed a strategy, which it believes will accomplish this objective through additional loans and advances, equity funding, and long term financing, which will enable the Company to operate for the coming year, there can be no assurance that funds will be available to the Company if and when needed.

Note_4_Prepaid_Expenses

Note 4 - Prepaid Expenses	12 Months Ended
	Aug. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Note 4 - Prepaid Expenses	'
	4.  PREPAID EXPENSES
	The following table provides details of the Company’s prepaid expenses as of August 31, 2013 and August 31, 2012:
		August 31,		August 31,
		2013		2012
	Rent	$	-	$	1,814
	Advances to manufacturer		60,377		-
		$	60,377	$	1,814
	Prepaid expenses of $60,377 consist of amounts advanced to manufacturing firms with respect to the development of Corlink prototypes and manufacturing moulds.   As at the date of this report the moulds have been completed.   During September 2013 the prototype for CorTab was received and tested and is mostly functional, ready for trials.

Note_5_Business_Combination

Note 5 - Business Combination	12 Months Ended
	Aug. 31, 2013
Business Combinations [Abstract]	'
Note 5 - Business Combination	'
	5.  BUSINESS COMBINATION
	On August 15, 2012, the Company entered into an acquisition agreement with CorTronix.  The officer and director of CorTronix, Yoel Palomino is also the officer and director of the Company, and is the developer of the technology held by CorTronix. CorTronix was incorporated solely for the purpose of this acquisition and its only operations were the development of a proprietary technology known as Corlink.  Corlink, is an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. Under the terms of the acquisition agreement CorTronix became a wholly owned subsidiary of the Company and is now the operational company which will continue with the commercialization of the technology it holds. Under the terms of the agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the Company. The Share Exchange Agreement was completed on September 11, 2012.
	CorTronix was incorporated under the laws of the State of Nevada on August 3, 2012 with authorized capital stock of 75,000,000 shares at $0.001 par value.  CorTronix was organized for the purpose of developing the Corlink technology.
	Pursuant to the terms and conditions of the acquisition agreement, we acquired 100% of the issued capital stock, 750,000 common shares; of CorTronix in exchange for 175,000,000 shares of the Company’s common stock, or 56.54% is the issued and outstanding share of the Company.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the business combination transaction date:
	Cash and cash equivalents	$	22,889
	Due from CorTronix		50,000
	Total identifiable assets	$	72,889
	Accounts payable	$	19,702
	Accrued interest		41,907
	Advances from related parties		34,358
	Notes payable		579,373
	Total identifiable liabilities	$	675,340
	Net identifiable assets	$	(602,451	)

Note_6_Lease_Agreement

Note 6 - Lease Agreement	12 Months Ended
	Aug. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Note 6 - Lease Agreement	'
	6. LEASE AGREEMENT
	On August 22, 2012, CorTronix leased office space in Hialeah, Florida on a one year lease with monthly rental payments of $1,814 per month including applicable taxes. The lease was renewed during the year for a further term ending on August 22, 2014 with monthly rental payments of $1,869 per month including applicable taxes.
	Under the terms of the above noted lease, the Company was required to provide a security deposit totaling $3,990. The security deposit is held by the Landlord without interest and shall be applied by the Landlord on account of the last month’s rent. The amount is included on the balance sheet of the Company as "Security Deposit."

Note_7_Loans_Payable

Note 7 - Loans Payable	12 Months Ended
	Aug. 31, 2013
Debt Disclosure [Abstract]	'
Note 7 - Loans Payable	'
	7. LOANS PAYABLE
	A summary of the principal balances of notes payable included in the consolidated balance sheet as of August 31, 2013:
	Date	Principal
	15-Apr-11	$	50,000
	6-May-11		50,000
	26-May-11		31,000
	30-Sep-11		49,798
	5-Oct-11		3,903
	5-Nov-11		8,570
	7-Nov-11		50,000
	10-Jan-12		1,995
	12-Mar-12		21,320
	27-Mar-12		200,000
	5-Apr-12		6,214
	10-Apr-12		100,000
	6-Jul-12		6,574
	9-Nov-12		150,000
	4-Feb-13		50,000
	2-Apr-13		40,000
		$	819,374
	At August 31, 2013, there was a balance of $819, 374 outstanding, due and payable to an unrelated third party.  These notes each have a one year term, bearing interest at ten (10%) percent per annum and are payable in full on the anniversary date.  The accrued interest for the fiscal year ended August 31, 2013 totaled $74,566 in respect of these loans. The Company did not make any payments towards accrued interest in the period, leaving an amount of $116,473 reflected on the Company’s balance sheet as Accrued Interest.
	Certain of these loans with a principal balance totaling $572,800 came due and payable in the current period at which time the lender verbally agreed to convert the loans to “demand” loans, with interest continuing to accrue until such time as they are paid in full.

Note_8_Significant_Transaction

Note 8 - Significant Transactions with Related Parties	12 Months Ended
	Aug. 31, 2013
Related Party Transactions [Abstract]	'
Significant Transactions with Related Parties	'
	8. SIGNIFICANT TRANSACTIONS WITH RELATED PARTY
	A former officer and director and 11% shareholder was due an amount totaling $34,358 (2012 - $34,358) which amount bears no interest, is unsecured and payable on demand.
	On August 15, 2012, we entered into an acquisition agreement with CorTronix (see Note 4 above), a company controlled by our Officer and Director, Yoel Palomino.  Under the terms of the acquisition agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the Company to Mr. Palomino who directed the issuance as to 122,500,000 shares issued to Mr. Palomino and 52,500,000 shares issued to Mr. Saer.   On September 11, 2012, the Company completed this transaction and CorTronix became a wholly-owned subsidiary of the Company.
	On August 3, 2012, the Company entered into a consulting agreement with Mr. Yoel Palomino, director and officer of the Company. Under the terms of the agreement, the Company will pay an annual salary of $125,000 to Mr. Palomino, payable weekly. During the fiscal year ended August 31, 2013, the Company made cash payments of $108,173 (August 31, 2012 -$9,615), leaving $16,827 (August 31, 2012 - $nil) due and payable to Mr. Palomino pursuant to the agreement.
	During the fiscal year ended August 31, 2013, Mr. Palomino advanced the Company $50,650 in order to settle certain operating expenses payable as they came due.
	During the fiscal year ended August 31, 2013, Mr. Jorge Saer, the Chief Technology Officer of the Company, invoiced a total amount of $48,000 for project development services. The Company made cash payments of $36,000, leaving $12,000 due and payable to Mr. Saer as at August 31, 2013.
	During the fiscal year ended August 31, 2013, an amount of $154,250 from the salary and wage expenses for Yoel Palomino and Jorge Saer was attributed to research and development with respect to the Company’s current software currently under development.

Note_9_Capital_Stock

Note 9 - Capital Stock	12 Months Ended
	Aug. 31, 2013
Equity [Abstract]	'
Note 9 - Capital Stock	'
	9. CAPITAL STOCK
	On August 15, 2012, we entered into an acquisition agreement with CorTronix.  Under the term of the acquisition agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the Company. On September 11, 2012, the Company completed this transaction. All outstanding shares have been restated to reflect the effect of the business combination.
	As at August 31, 2013, the Company had a total of 287,000,000 shares of common stock issued and outstanding.

Note_10_Income_Taxes

Note 10 - Income Taxes	12 Months Ended
	Aug. 31, 2013
Income Tax Disclosure [Abstract]	'
Note 10 - Income Taxes	'
	10.  INCOME TAXES
	The Company has losses carried forward for income tax purposes for August 31, 2013. There are no current or deferred tax expenses for the period ended August 31, 2013 due to the Company’s loss position. The Company has fully reserved for any benefits of these losses. The deferred tax consequences of temporary differences in reporting items for financial statement and income tax purposes are recognized, as appropriate. Realization of the future tax benefits related to the deferred tax assets is dependent on many factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period.
	Management has considered these factors in reaching its conclusion as to the valuation allowance for financial reporting purposes.
		31-Aug-13			31-Aug-12
	Operating loss carry forward		450,179			10,936
	Net operating loss carry forward		450,179			10,936
	Effective Tax Rate, Federal and State		40.5	%		40.5	%
	Deferred Tax Assets		182,300			4,400
	Less: Valuation Allowance		(182,300	)		(4,400	)
	Net deferred tax asset	$	0		$	0
	The valuation allowance for deferred tax assets as of August 31, 2013 and 2012 was $177,900 and $4,400 respectively. In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of August 31, 2013 and 2012, and recorded a full valuation allowance.
	Reconciliation between the statutory rate and the effective tax rate is as follows at August 31:
		2013			2012
	Federal and State, statutory tax rate		40.5	%		40.5	%
	Permanent difference and other		-	%		-	%
	Effective tax rate		40.5	%		40.5	%
	The net federal operating loss carry forward will expire between 2032 and 2033. This carry forward may be limited upon the consummation of a business combination under IRC Section 381.

Note_11_Subsequent_Events

Note 11 - Subsequent Events	12 Months Ended
	Aug. 31, 2013
Subsequent Events [Abstract]	'
Note 11 - Subsequent Events	'
	11.  SUBSEQUENT EVENTS
	On July 25, 2013, the Company entered into a marketing agreement with Global Investment Strategies S.A. LLC., a company with offices in Saudi Arabia (“GIS”) whereby GIS is granted the exclusive license for the Middle East and will provide support, management and personnel to make strategic introductions to end users of the Cortronix technologies, including but not limited to hospitals, government agencies, the military and certain airlines in the middle east and other countries.   The Company is not requested to pay any payments, fees, royalties or other consideration other than to issue a total of 52,500,000 shares of the common stock of the Company which were issued on November 19, 2013.   The contract also gives GIS the right to appoint a member to the Board of Directors, however, no appointment has yet been made.  The agreement has an initial term of five years and  renews automatically for an additional five years unless written notice is provided by either party.
	On September 6, 2013, the Company entered into a consulting and investor relations agreement with Maplehurst Investment Group, LLC (“Maplehurst”).    The Company had previously during November 2012, engaged Maplehurst to provide consulting and investor relations services for a fee of $5,000 per month.  Under the terms of the new agreement, the Company agreed to settle the outstanding amount of $40,000 under the contract with Maplehurst by way of the issuance of 10,000,000 shares of the common stock of the Company and Maplehurst agreed to provide services under the contract for an additional twelve month period for no further consideration.   The shares were issued on November 19, 2013.
	During September 2013 the prototype for Cortab was received and tested and is mostly functional .ready for trials.
	On December 30, 2013, the Company received funds in the amount of $15,500 from a third party. The loan is a one-year unsecured promissory note with interest at a rate of 18% per 365 day period. After the maturity date, the note shall accrue interest at a rate of 18%, payable semi-annually, plus a penalty of 6% per 30 day period. Should the principal amount of the note and all accrued interest not be repaid within 30 days after the maturity date, the Company should pay a penalty in the form of shares of common stock equal to 18,750 shares per month pro-rated daily.
	The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there were no other events to disclose.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	These consolidated financial statements include the accounts of CorTronix Biomedical Advancement Technologies Inc., and its wholly-owned subsidiary, CorTronix Technologies Inc. All intercompany balances and transactions have been eliminated in consolidation.
Development- Stage	'
	Development- Stage
	CorTronix Biomedical Advancement Technologies Inc. is a development-stage company as defined in Accounting Standards Codification (“ASC”) 915 Development-Stage Entities, as it is developing an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. There have been no revenues from planned principal operations or sales from August 3, 2012 (date of inception through August 31, 2013. Consequently, cumulative amounts are presented in these consolidated financial statements.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of the consolidated statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are recorded at cost. Depreciation and amortization of property and equipment are calculated using the straight-line method over the assets’ estimated useful lives as follows: computer hardware and software (three years), leasehold improvements (the shorter of five years or lease life), furniture and fixtures (five years) and equipment (five to ten years).
	Maintenance and repairs are charged to expense as incurred. Significant renewals and betterments are capitalized. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations.
Research and Development	'
	Research and Development
	Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for project development activities, and that have alternative future uses, both in project development, marketing or sales, will be capitalized classified as property, plant and equipment and depreciated over their estimated useful lives. To date, research costs, including amounts paid for man hours allocated to ongoing technology development,  have been expensed when incurred.
Accounting Methods	'
	Accounting Methods
	The Company recognizes income and expenses based on the accrual method of accounting.
Dividend Policy	'
	Dividend Policy
	The Company has not yet adopted a policy regarding payment of dividends.
Basic and Diluted Net Income (loss) Per Share	'
	Basic and Diluted Net Income (loss) Per Share
	Basic net income (loss) per share amounts are computed based on the weighted average number of shares actually outstanding. Diluted net income (loss) per share amounts are computed using the weighted average number of common and common equivalent shares outstanding as if shares had been issued on the exercise of any common share rights unless the exercise becomes antidilutive and then the basic and diluted per share amounts are the same.
Income Taxes	'
	Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under the liability method deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax bases of the assets and liabilities and are measured using the enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recorded, when it is more likely than not, that such tax benefits will not be realized. As of August 31, 2013, the Company had a deferred tax asset and related valuation allowance of $182,000, which begins to expire in 2032, related to its current operations.
	Section 382 of the Internal Revenue Code imposes limitations on net loss carryforwards when there is a change in control. Due to the change of business and management, the Company has assumed loss carryforwards related to the Company’s prior operations will not be available to offset future taxable income.
Advertising and Market Development	'
	Advertising and Market Development
	The Company expenses advertising and market development costs as incurred.
Impairment of Long-lived Assets	'
	Impairment of Long-lived Assets
	The Company reviews and evaluates long-lived assets for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The assets are subject to impairment consideration under ASC 360-10-35-17 if events or circumstances indicate that their carrying amounts might not be recoverable. When the Company determines that an impairment analysis should be done, the analysis will be performed using rules of ASC 930-360-35, Asset Impairment, and 360-10-15-3 through 15-5, Impairment or Disposal of Long-Lived Assets.
Financial Instruments	'
	Financial Instruments
	The carrying amounts of financial instruments are considered by management to be their fair value due to their short term maturities.
Estimates and Assumptions	'
	Estimates and Assumptions
	Management uses estimates and assumptions in preparing financial statements in accordance with general accepted accounting principles. Those estimates and assumptions affect the reported amounts of the assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were assumed in preparing these financial statements.
Statement of Cash Flows	'
	Statement of Cash Flows
	For the purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There are several new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of May 31, 2013, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company.

Note_4_Prepaid_Expenses_Tables

Note 4 - Prepaid Expenses (Tables)	12 Months Ended
	Aug. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Prepaid expenses	'
		August 31,		August 31,
		2013		2012
	Rent	$	-	$	1,814
	Advances to manufacturer		60,377		-
		$	60,377	$	1,814

Note_5_Business_Combination_Ta

Note 5 - Business Combination (Tables)	12 Months Ended
	Aug. 31, 2013
Business Combinations [Abstract]	'
Schedule of net identifiable assets, business combination	'
	Cash and cash equivalents	$	22,889
	Due from CorTronix		50,000
	Total identifiable assets	$	72,889
	Accounts payable	$	19,702
	Accrued interest		41,907
	Advances from related parties		34,358
	Notes payable		579,373
	Total identifiable liabilities	$	675,340
	Net identifiable assets	$	(602,451	)

Note_7_Loans_Payable_Tables

Note 7 - Loans Payable (Tables)	12 Months Ended
	Aug. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Loans Payable	'
	Date	Principal
	15-Apr-11	$	50,000
	6-May-11		50,000
	26-May-11		31,000
	30-Sep-11		49,798
	5-Oct-11		3,903
	5-Nov-11		8,570
	7-Nov-11		50,000
	10-Jan-12		1,995
	12-Mar-12		21,320
	27-Mar-12		200,000
	5-Apr-12		6,214
	10-Apr-12		100,000
	6-Jul-12		6,574
	9-Nov-12		150,000
	4-Feb-13		50,000
	2-Apr-13		40,000
		$	819,374

Note_10_Income_Taxes_Tables

Note 10 - Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2013
Income Tax Disclosure [Abstract]	'
Deferred Tax Assets	'
		31-Aug-13			31-Aug-12
	Operating loss carry forward		450,179			10,936
	Net operating loss carry forward		450,179			10,936
	Effective Tax Rate, Federal and State		40.5	%		40.5	%
	Deferred Tax Assets		182,300			4,400
	Less: Valuation Allowance		(182,300	)		(4,400	)
	Net deferred tax asset	$	0		$	0
Effective Income Tax Rate	'
		2013			2012
	Federal and State, statutory tax rate		40.5	%		40.5	%
	Permanent difference and other		-	%		-	%
	Effective tax rate		40.5	%		40.5	%

Note_1_Organization_and_Basis_1

Note 1 - Organization and Basis of Presentation (Details Narrative) (USD $)	Aug. 31, 2013	Sep. 11, 2012	Aug. 31, 2012	Oct. 04, 2006
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'
Common stock, shares authorized	800,000,000	'	800,000,000	100,000,000
Common stock, par value	$0.00	'	$0.00	$0.00
Shares issued, share exchange agreement	'	175,000,000	'	'

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details Narrative) (USD $)	Aug. 31, 2013
Accounting Policies [Abstract]	'
Term of maturity or less to equal cash equivalents	3
Computer hardware and software, useful life in years	3
Leasehold Improvements, useful life in years	5
Furniture and Fixtures, useful life in years	5
Equipment, useful life in years, minimum	5
Equipment, useful life in years, maximum	10
Valuation allowance	$182,000
Year in which deferred tax assets begin to expire	'2032

Note_4_Prepaid_Expenses_Prepai

Note 4 - Prepaid Expenses - Prepaid expenses (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'	'
Rent	'	$1,814
Advances to manufacturer	60,377	'
[TotalPrepaid]	$60,377	$1,814

Note_4_Prepaid_Expenses_Detail

Note 4 - Prepaid Expenses (Details Narrative) (USD $)	Aug. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Prepaid expenses, manufacturing deposits	$60,377

Note_5_Business_Combination_Sc

Note 5 - Business Combination - Schedule of net identifiable assets, business combination (Details) (USD $)	Sep. 11, 2012
Business Combinations [Abstract]	'
Cash and cash equivalents	$22,889
Due from CorTronix	50,000
Total identifiable assets	72,889
Accounts payable	19,702
Accrued interest	41,907
Advances from related parties	34,358
Notes payable	579,373
Total identifiable liabilities	675,340
Net identifiable assets	($602,451)

Note_5_Business_Combination_De

Note 5 - Business Combination (Details Narrative) (USD $)	Sep. 11, 2012
Business Combinations [Abstract]	'
Shares issued, share exchange agreement	175,000,000
Authorized share capital - Cortronix Technologies Inc.	75,000,000
Par Value, Cortronix Technologies Inc.	$0.00
Percent Cortronix Technologies Inc, acquired	100.00%
Shares outstanding, Cortronix Technologies Inc.	750,000
Percent shares issued for acquisition	56.54%

Note_6_Lease_Agreement_Details

Note 6 - Lease Agreement (Details Narrative) (USD $)	Aug. 31, 2013	Aug. 22, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'
Term of lease, in years	1	1
Monthly rental payment	$1,869	$1,814
Security deposit	'	$3,990

Note_7_Loans_Payable_Schedule_

Note 7 - Loans Payable - Schedule of Loans Payable (Details) (USD $)

Aug. 31, 2013

Apr. 02, 2013

Feb. 04, 2013

Nov. 09, 2012

Jul. 06, 2012

Apr. 10, 2012

Apr. 05, 2012

Mar. 27, 2012

Mar. 12, 2012

Jan. 10, 2012

Nov. 07, 2011

Nov. 05, 2011

Oct. 05, 2011

Sep. 30, 2011

26-May-11

6-May-11

Apr. 15, 2011

Debt Disclosure [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal

$819,374

$40,000

$50,000

$150,000

$6,574

$100,000

$6,214

$200,000

$21,320

$1,995

$50,000

$8,570

$3,903

$49,798

$31,000

$50,000

$50,000

Note_7_Loans_Payable_Details_N

Note 7 - Loans Payable (Details Narrative) (USD $)	1 Months Ended	12 Months Ended	13 Months Ended
	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2013
Debt Disclosure [Abstract]	'	'	'
Notes payable	'	$819,374	$819,374
Term of loans, in years	'	1	1
Interest rate per annum	'	10.00%	10.00%
Accrued interest	'	74,566	74,566
Accrued interest	'	116,473	116,473
Loans due and converted to demand, amount	'	$572,800	$572,800

Note_8_Significant_Transaction1

Note 8 - Significant Transactions with Related Parties (Details Narrative) (USD $)	1 Months Ended	12 Months Ended
	Aug. 31, 2012	Aug. 31, 2013	Sep. 11, 2012	Aug. 04, 2012
Related Party Transactions [Abstract]	'	'	'	'
Amount due shareholder and former officer	$34,358	$34,358	'	'
Percent ownership	'	11.00%	'	'
Yoel Palomino	'	'	'	'
Annual Salary	'	'	'	125,000
Salary paid	9,615	108,173	'	'
Amount due and payable	'	16,827	'	'
Amounts advanced for expenses	'	50,650	'	'
Jorge Saer	'	'	'	'
Fees invoiced	'	48,000	'	'
Payments	'	36,000	'	'
Amount due and payable	'	12,000	'	'
Salaries, wages and fees attributed to research and development	'	$154,250	'	'
Shares issued, share exchange agreement	'	'	175,000,000	'
Shares issued to Mr. Yoel Palomino	'	'	122,500,000	'
Shares issued to Mr. Jorge Saer	'	'	52,500,000	'

Note_9_Capital_Stock_Details_N

Note 9 - Capital Stock (Details Narrative)	Aug. 31, 2013	Sep. 11, 2012	Aug. 31, 2012
Equity [Abstract]	'	'	'
Shares issued, share exchange agreement	'	175,000,000	'
Common stock, shares issued	287,000,000	'	175,000,000

Note_10_Income_Taxes_Deferred_

Note 10 - Income Taxes - Deferred Tax Assets (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Operating loss carry forward	$450,179	$10,936
Net operating loss carry forward	450,179	10,936
Effective Tax Rate	40.50%	40.50%
Deferred Tax Assets	182,300	4,400
Less: Valuation Allowance	-182,300	-4,400
Net deferred tax asset	$182,300	$4,400

Note_10_Income_Taxes_Effective

Note 10 - Income Taxes - Effective Income Tax Rate (Details)	1 Months Ended	12 Months Ended
	Aug. 31, 2012	Aug. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Federal statutory tax rate	40.50%	40.50%
Permanent difference and other	0.00%	0.00%
Effective tax rate	40.50%	40.50%

Note_10_Income_Taxes_Details_N

Note 10 - Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Valuation Allowance	$177,900	$4,400
Year loss carryforwards begin to expire	1-Jan-32	'
Year loss carryforwards fully expire	'2033-01-01	'

Note_11_Subsequent_Events_Deta

Note 11 - Subsequent Events (Details Narrative) (USD $)	Dec. 30, 2013	Nov. 19, 2013	Sep. 06, 2013	Jul. 25, 2013
Subsequent Events [Abstract]	'	'	'	'
Shares issued GIS	'	52,500,000	'	'
Term Agreement GIS	'	5	'	'
Term Renewal GIS	'	5	'	'
Maplehurst	'	'	'	'
Monthly payment	'	'	$5,000	'
Amount settled with shares	'	'	40,000	'
Shares issued Maplehurst	'	'	'	10,000,000
Term months, contract	'	'	12	'
Funds received	$15,500	'	'	'
Interest rate	18.00%	'	'	'
Interest rate after maturity	18.00%	'	'	'
Interest penalty after maturity, per period	6.00%	'	'	'
Stock penalty monthly	18,750	'	'	'